StockGlow

Arcutis Biotherapeutics, Inc. (ARQT)

Develops topical creams treating psoriasis and eczema.

$28.42+0.02%Healthcare
Compare ARQT with
StockGlow Score
88
Bullish
BearishBullish
1 year ago+98.9%

The outlook

Arcutis trades at $28.42 and sits firmly in the upper portion of its 52-week range, well above both its 50- and 200-day moving averages. Analysts are predominantly bullish with a "Strong Buy" consensus, and the average price target sits roughly 22% above the current price. The overall data picture leans decidedly constructive.

What’s behind the score

Analyst consensusStrong Buy — 1.5 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range81% of the way from its 52-week low to high
Price targetAvg target +22% vs current price

Analyst price target

~12-month · 8 analysts
$34.63average target+21.8% vs now
Now $28.42
Low $33.00High $36.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$3.55B
52-wk high
$31.77
52-wk low
$13.70
50-day avg
$24.77
200-day avg
$25.16
Trailing P/E
—

Similar stocks

STOKStoke Therapeutics, Inc.$29.39+0.27%CCCCC4 Therapeutics, Inc.$3.55-1.11%CRNXCrinetics Pharmaceuticals, Inc.$83.86+0.01%ALXOALX Oncology Holdings Inc.$1.99-1.49%TVTXTravere Therapeutics, Inc.$55.91-1.36%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy